The Latest Urologic Oncology Journal Articles

Keep up to date with the latest in urologic oncology. Check out the latest diabetes articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily

• Surgical Management of Retrocrural Disease in Germ Cell Tumors: Outcomes and Evolution of Practice.12th November 2020
  Residual retrocrural disease in testis cancer following chemotherapy is a surgical challenge. We sought to assess the outcomes and evolution with surgical management of residual retrocrural disease.We identified 2,788 testicular cancer patients from 1990-2010 who underwent retroperitoneal surgery for metastatic testicular cancer at our institution. Patients who also underwent post-chemotherapy staged or concurrent retrocrural dissections […]
• Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.11th November 2020
  Although grading systems have been proposed for chromophobe renal cell carcinoma (ChRCC), including a three-tiered system by Paner et al (Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 2010;34:1233-40), none have gained clinical […]
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.11th November 2020
  To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).The panel performed a literature review of […]
• The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.7th November 2020
  We assessd the long-term outcomes from a large prospective cohort of men diagnosed with prostate cancer managed with active surveillance and determined the clinical prognostic factors that may predict the risk of metastases.We retrospectively reviewed data of men enrolled on active surveillance at our institution between 1990 and 2018 with low or intermediate risk disease […]
• Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.6th November 2020
  Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown clinical benefit in a subset of patients, but the mechanistic basis and biomarkers remain elusive.To identify mechanisms and response indicators for the antitumor efficacy of taxane-platinum combinations […]
• Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.5th November 2020
  Distinguishing indolent from aggressive prostate cancer remains a key challenge for decision making regarding prostate cancer management. A growing number of biomarkers are now available to help address this need, but these have rarely been examined together in the same patients to determine their potentially additive value.To determine whether two previously validated plasma markers (transforming […]
• Association Between African American Race and Clinical Outcomes in Men Treated for Low-Risk Prostate Cancer With Active Surveillance.3rd November 2020
  There is concern that African American men with low-risk prostate cancer may harbor more aggressive disease than non-Hispanic White men. Therefore, it is unclear whether active surveillance is a safe option for African American men.To compare clinical outcomes of African American and non-Hispanic White men with low-risk prostate cancer managed with active surveillance.Retrospective cohort study […]
• Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.29th October 2020
  Focal instead of whole gland ablation for prostate cancer has been proposed to decrease treatment morbidity. We sought to determine differences in erectile function and urinary continence after focal and whole gland ablation for prostate cancer.From 2009 to 2018, 346 patients underwent high intensity focused ultrasound or cryotherapy for prostate cancer. Urinary continence was defined […]
• Performance of Prostate Health Index (PHI) in Biopsy-Naïve Black Men.26th October 2020
  Prostate Health Index (PHI) is validated for prostate cancer (PCa) detection but has not been well validated for Gleason grade group (GG) 2-5 PCa detection in Black men. We hypothesize that PHI has greater accuracy than PSA for detection of GG2-5 PCa. We estimated probability of overall and GG2-5 PCa across previously established PHI ranges […]
• An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.23rd October 2020
  In the USA, it is unknown whether metastatic prostate cancer incidence has continued to increase and whether racial differences have persisted.Combining multiple imputation with age and delay adjustment, we provide an up-to-date, comprehensive assessment of US prostate cancer incidence trends by stage and race.From Surveillance Epidemiology and End Results (SEER)-18, 774 240 prostate cancer cases […]
• Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere – An Analysis of US Clinical Data.22nd October 2020
  Non-adherence to dosing schedules for androgen deprivation therapy (ADT) increases risk of testosterone (T) escape for prostate cancer (PCa) patients. Two approved formulations of leuprolide acetate (LA), the most commonly prescribed ADT in the US, use different extended-release delivery technologies: an in situ gel and microspheres. We evaluated the prevalence and impact of late dosing […]
• Hood Technique for Robotic Radical Prostatectomy-Preserving Periurethral Anatomical Structures in the Space of Retzius and Sparing the Pouch of Douglas, Enabling Early Return of Continence Without Compromising Surgical Margin Rates.17th October 2020
  A common side effect following radical prostatectomy is urinary incontinence. Here, we describe a novel surgical technique to reduce postoperative urinary incontinence and facilitate early return of continence.To describe the novel “hood technique” for robotic-assisted radical prostatectomy (RARP).This is an institutional review board-approved prospective study of 300 patients (median age 64 yr) with localized prostate […]
• False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.14th October 2020
  False positive multiparametric magnetic resonance imaging (mpMRI) phenotypes prompt unnecessary biopsies. The Prostate MRI Imaging Study (PROMIS) provides a unique opportunity to explore such phenotypes in biopsy-naïve men with raised prostate-specific antigen (PSA) and suspected cancer.To compare mpMRI lesions in men with/without significant cancer on transperineal mapping biopsy (TPM).PROMIS participants (n=235) underwent mpMRI followed by […]
• The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.13th October 2020
  Clear cell papillary renal cell carcinoma (CCPRCC) is a recently described tumor entity. Several questions remain about its epidemiology, molecular features, and clinical behavior.To comprehensively evaluate clinicopathologic and molecular features of CCPRCC, and compare it with more common kidney cancer subtypes.We identified 89 CCPRCC patients and compared their clinicopathologic features with 1120 localized clear cell […]
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.11th October 2020
  To present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC).The working panel performed a literature review of […]
• Timing, Patterns and Predictors of 90-days Readmission Rate after Robotic Radical Cystectomy.9th October 2020
  To examine the timing, patterns and predictors of 90-day readmission after robotic radical cystectomy.From September 2009 to March 2017, 271 consecutive patients undergoing robotic radical cystectomy (RRC) with intent to cure bladder cancer (intracorporeal diversion N=253, 93%) were identified from our prospectively collated institutional database. Readmission was defined as any subsequent inpatient admission or unplanned […]
• Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naïve Advanced Prostate Cancer Patients?9th October 2020
  To study baseline serum testosterone’s prognostic value in hormone naïve advanced prostate cancer patients receiving continuous androgen deprivation therapy.The study population undergoing continuous androgen deprivation therapy (agonist or antagonist) with 1-year follow-up was pooled for post-hoc analysis from two large prospective, randomized, parallel-arm phase 3b trials (NCT00295750-Global; NCT00928434-USA). Survival end-points were evaluated for baseline serum […]
• External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.7th October 2020
  The nomogram reported by Gandaglia et al (The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy. Eur Urol 2020;77:733-41) predicting extracapsular extension (ECE) or seminal vesicle invasion (SVI) has been developed using multiparametric […]
• Erectile Dysfunction is a Transient Complication of Prostate Biopsy: A Systematic Review and Metanalysis.7th October 2020
  Because the association between erectile dysfunction (ED) and prostate biopsy is variable in the available literature, we sought to perform a systematic review and meta-analysis of sexual dysfunction in males within six months of prostate biopsy.We conducted a systematic literature search in four databases [MEDLINE (via PubMed), Embase (via Ovid), Web of Science, and The […]
• Application of the PRECISION Trial Biopsy Strategy to a Contemporary MRI-Targeted Biopsy Cohort: How Many Clinically Significant Prostate Cancers are Missed?7th October 2020
  To demonstrate the generalizability of PRECISION findings and apply the PRECISION biopsy strategy to a contemporary cohort to characterize cancers missed by employing this strategy.629 men biopsied between 2/2015-9/2018 met PRECISION inclusion criteria. Men with PI-RADS 1-2 MRI were only biopsied if high clinical suspicion for cancer. Missed cancers were defined as prostate cancer (PCa) […]
• Predicting Pathologic Tumor Size in Prostate Cancer Based on Multiparametric Prostate MRI and Preoperative Findings.7th October 2020
  Oncologic efficacy of focal therapies in prostate cancer (PCa) depends heavily on accurate tumor size estimation. We aim to evaluate the agreement between radiologic tumor size (RTS) and pathologic tumor size (PTS) and identify predictors of PTS.This single-arm study cohort included all consecutive patients with biopsy-proven PCa and a corresponding PIRADSv2 ≥3 index tumor on […]
• Is the Toxicity of Salvage Prostatectomy Related to the Primary Prostate Cancer Therapy Received?6th October 2020
  To compare the toxicity profile and oncological outcome of salvage radical prostatectomy (SRP) following focal therapy (FT) versus SRP after radiation therapies (RT) – external beam radiation therapy (EBRT) or brachytherapy (BT).Data concerning all men undergoing SRP for recurrent prostate cancer after either FT, EBRT or BT were retrospectively collected from 4 high volume surgical […]
• Prospective Validation of Vesical Imaging-Reporting and Data System (VI-RADS) Using a Next-Generation Magnetic Resonance Imaging Scanner: Is Denoising Deep Learning Reconstruction Useful?6th October 2020
  The Vesical Imaging Reporting and Data System (VI-RADS) was launched in 2018 to standardize reporting of magnetic resonance imaging (MRI) for bladder cancer (BC). This study aimed to prospectively validate VI-RADS using a next-generation MRI scanner and to investigate the usefulness of denoising deep learning reconstruction (dDLR).We prospectively enrolled 98 patients who underwent bladder multiparametric […]
• Surgeon Scorecards Improve Muscle Sampling on TURBTs and Recurrence Outcomes in Patients with NMIBC.6th October 2020
  The presence of detrusor muscle (DM) is essential for accurate staging of T1 cancers. DM presence can be a quality indicator of transurethral resection of bladder tumor (TURBT) for NMIBC. We hypothesized that increasing surgeon awareness of personal and institutional DM sampling rates could improve resection quality and long-term oncologic outcomes.A retrospective review of TURBTs […]
• MRI-guided transurethral ultrasound ablation of prostate cancer.6th October 2020
  MRI-guided transurethral ultrasound ablation (TULSA) uses directional thermal ultrasound under MRI thermometry feedback control for prostatic ablation. We report 12-month outcomes from a prospective multicenter trial (TACT).115 men with favorable to intermediate risk prostate cancer across 13 centers were treated with. whole-gland ablation sparing the urethra and apical sphincter. The co-primary 12-month endpoints were safety […]
• Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.5th October 2020
  The PROfound trial evaluated the PARP inhibitor olaparib in metastatic castration-resistant prostate cancers harboring alterations in BRCA1/2 and ATM (cohort A) and in 12 other homologous recombination repair genes (cohort B). Olaparib led to more objective responses and longer radiographic progression-free survival (rPFS) than the control in cohort A and when cohorts A and B […]
• Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.4th October 2020
  There is no universally accepted definition for prostate-specific antigen (PSA) progression. However, changes in PSA in patients with castration-resistant prostate cancer (CRPC) are used to inform treatment decisions.To determine whether the Prostate Cancer Working Group 2 (PCWG2) definition of PSA progression is adequate to predict radiographic or clinical progression in enzalutamide-treated men with nonmetastatic CRPC […]
• Quality of Bladder Cancer Information on YouTube.4th October 2020
  Dissemination of misinformation through social media is a major societal issue. Bladder cancer is the second most common urological cancer in the world, but there are limited data on the quality of bladder cancer information on social networks. Our objective was to characterize the quality of information and presence of misinformation about bladder cancer on […]
• Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy.28th September 2020
  Contemporary biopsy methods were used to determine the success rate of hemigland cryoablation as a primary treatment for prostate cancer. Previous studies, often including men at low risk, have used magnetic resonance imaging guided biopsy to a variable extent. Here, we uniformly used the new diagnostic modality to study all men, each with clinically significant […]
• Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.26th September 2020
  A survival benefit was demonstrated for patients with low-volume metastatic prostate cancer (mPCa) when local radiotherapy was added to androgen deprivation therapy (ADT).To determine the effect of ADT combined with external beam radiotherapy (EBRT) to the prostate on health-related quality of life (HRQoL) of patients with primary bone mPCa.The HORRAD trial is a multicentre randomised […]
• Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita.25th September 2020
  Bladder cancer is a major urological disease, with approximately 550 000 new cases diagnosed in 2018.We examined gender-specific incidence and mortality patterns, and trends of bladder cancer from a global perspective. We further investigated their associations with tobacco use and gross domestic product (GDP) per capita.We retrieved data on the incidence and mortality of bladder […]
• Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier.25th September 2020
  Renal oncocytoma (RO) accounts for 5% of renal cancers and generally behaves as a benign tumor with favorable long-term prognosis. It is difficult to confidently distinguish between benign RO and other renal malignancies, particularly chromophobe renal cell carcinoma (chRCC). Therefore, RO is often managed aggressively with surgery. We sought to identify molecular biomarkers to distinguish […]
• Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.22nd September 2020
  The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer to Part I for discussion of the management of patients with biochemical recurrence without metastatic disease after exhaustion of local treatment options as well as […]
• Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.22nd September 2020
  The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic disease after exhaustion of local treatment options as well as those with metastatic hormone-sensitive prostate cancer. Please refer to Part II for discussion of the […]
• Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration.20th September 2020
  Despite being the most frequent renal fusion anomaly, tumors arising from horseshoe kidneys (HSKs) are extremely rare and management guidance is lacking.To evaluate the perioperative, oncological, and functional outcomes of surgically treated HSK tumors.A retrospective, multicenter cohort study of 43 HSK tumors in 40 patients was conducted, and technical description of the surgical approach has […]
• Hybrid Indocyanine Green-99mTc-nanocolloid for Single-photon Emission Computed Tomography and Combined Radio- and Fluorescence-guided Sentinel Node Biopsy in Penile Cancer: Results of 740 Inguinal Basins Assessed at a Single Institution.20th September 2020
  Sentinel node (SN) biopsy in penile cancer (PeCa) is typically performed using 99mTc-nanocolloid and blue dye. Recent reports suggested that the hybrid (radioactive and fluorescent) tracer indocyanine green (ICG)-99mTc-nanocolloid may improve intraoperative optical SN identification.The current study aimed to confirm the reliability of ICG-99mTc-nanocolloid and to assess whether blue dye is still of added value.A […]
• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.20th September 2020
  We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician’s choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final analysis […]
• A Urine Exosome Gene Expression Panel Distinguishes Between Indolent and Aggressive Prostate Cancers at Biopsy.18th September 2020
  Prostate cancer is predominantly indolent at diagnosis with a small fraction (15-25%) representing aggressive subtype [Gleason score (GS) 7-10], which is prone to metastatic progression. It is critical to explore non-invasive assays for the early detection of this aggressive subtype, when it still can be treated effectively. Additionally, there is an emerging need to develop […]
• Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging.18th September 2020
  The feasibility and efficacy of robot-assisted radical prostatectomy (RARP) in locally advanced prostate cancer (PCa) patients with iT3 lesion at magnetic resonance imaging (MRI) are currently not explored.To describe our revised RARP technique (ie, superextended RARP [SE-RARP]) for PCa patients with posterior iT3a or iT3b at MRI.Data from 89 patients with posterior iT3a or T3b […]
• A Systematic Review and Meta-Analysis of the Significance of Body Mass Index on Kidney Cancer Outcomes.18th September 2020
  Obesity is a well-known risk factor for kidney cancer incidence. However, a number of studies have demonstrated more favorable kidney cancer prognosis in patients with elevated body mass index (BMI) conferring a survival advantage, termed ‘the obesity paradox’. We aimed to evaluate the association between BMI and kidney cancer outcomes (progression-free survival (PFS), cancer specific […]
• Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.17th September 2020
  Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free […]
• Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.16th September 2020
  Restaging of prostate cancer in patients with biochemical recurrence (BCR) after radical treatment remains a challenging clinical scenario as current imaging modalities are suboptimal. To date, PSMA PET/CT seems to represent a very promising diagnostic tool in this setting. Therefore, we evaluated the detection rate (DR) of several PET/CT PSMA-based tracers in the restaging of […]
• Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy, and Retroperitoneal Lymph Node Dissection for the Management of Early-Stage Testicular Germ Cell Tumors: A Systematic Review.11th September 2020
  Cancer-specific survival for men with early-stage (Stage I-IIB) testicular germ cell tumors (TGCT) is greater than 90% with any management strategy. The data regarding the comparative effectiveness of surveillance, primary chemotherapy, radiotherapy, and retroperitoneal lymph node dissection (RPLND) was synthesized with a focus on oncologic outcomes, patient-reported outcomes, and short- and long-term toxicities.PubMed, Embase® and […]
• Apalutamide and Overall Survival in Prostate Cancer.10th September 2020
  The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.We report the prespecified event-driven final analysis for OS.A total of 1207 […]
• Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.10th September 2020
  Life expectancy has become a core consideration in prostate cancer care. While multiple prediction tools exist to support decision-making, their discriminative ability remains modest, which hamper usage and utility. We examined whether combining patient-reported and claims-based health measures into prediction models improves performance.Using SEER-CAHPS, we identified men ≥65 years old diagnosed with prostate cancer from […]
• Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.9th September 2020
  Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at […]
• High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.9th September 2020
  We report outcomes of hemigland high intensity focused ultrasound ablation as primary treatment for localized prostate cancer in the United States.A total of 100 consecutive men underwent hemigland high intensity focused ultrasound (December 2015 to December 2019). Primary end point was treatment failure, defined as Grade Group 2 or greater on followup prostate biopsy, radical […]
• Outcomes in Patients with Renal Cell Carcinoma Undergoing Inferior Vena Cava Ligation without Reconstruction versus Thrombectomy: A Retrospective, Case-Controlled Study.9th September 2020
  Radical nephrectomy with tumor thrombectomy is considered standard of care in patients with renal cell carcinoma (RCC). Surgical ligation and interruption of the inferior vena cava (IVC), however, is sometimes necessary when the tumor thrombus invades the IVC wall. This study assesses the outcomes in patients with RCC undergoing IVC ligation compared to IVC thrombectomy.We […]
• Androgen Deprivation Therapy in Men With Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2.8th September 2020
  TMPRSS2 is a host co-receptor for cell entry of SARS-CoV-2. One prior report suggested that use of androgen deprivation therapy (ADT), which downregulates TMPRSS2, may protect men with prostate cancer from infection.Cohort study of a prospective registry of all patients tested for SARS-CoV-2 between March 12 and June 10, 2020, with complete follow-up until disease […]
• Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes Following Radical Cystectomy.8th September 2020
  Frailty is associated with adverse outcomes following radical cystectomy. Prospective tools to identify factors affecting outcomes are needed. We describe a novel electronic rapid fitness assessment to evaluate geriatric patients undergoing radical cystectomy.Prior to undergoing radical cystectomy between February 2015 and February 2018, 80 patients over the age of 75 completed the electronic rapid fitness […]
• Clinical Utility of 4Kscore, ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High-Grade Prostate Cancer.8th September 2020
  We aimed to evaluate 4Kscore and ExosomeDx with multiparametric magnetic resonance imaging (mpMRI) in the detection of high-grade prostate cancer (PCa) and number of biopsies avoided.Patients had one liquid biomarker test with or without mpMRI. High-grade PCa was defined as Gleason grade group (GG) ≥2. The overall number of avoided biopsies (with GG≤1), and number […]
• Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing.8th September 2020
  BackgroundTo explore the genomic profiles of Chinese patients with castration-sensitive prostate cancer(CSPC) and those with metastatic castration-resistant prostate cancer(mCRPC) via germline and circulating tumor DNA(ctDNA) sequencing.MethodsA hybridization capture-based next-generation sequencing assay was used to identify germline and somatic alterations in 50 genes, including androgen receptor(AR) pathway genes, DNA damage repair(DDR) pathway genes, TP53, and RB1.ResultsWe […]
• Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.2nd September 2020
  Perioperative chemotherapy (neoadjuvant or adjuvant) has been developed to increase overall survival for nonmetastatic muscle-invasive bladder cancer (MIBC). Retrospective studies or prospective phase II trials have been reported to use dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC). As dd-MVAC has shown higher response rates in metastatic disease, better efficacy is […]
• The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage.29th August 2020
  The dogma that urine is sterile has been overturned and dysbiosis of the urinary microbiome has been linked to many urological disorders. We tested the hypothesis that the urinary microbial composition may be different between men with or without bladder cancer in catheter-collected urines, bladder washouts and midstream voided urines, and may be dependent on […]
• The Risk of New Onset Dementia And/Or Alzheimer’s Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis.29th August 2020
  Androgen deprivation therapy (ADT) is a standard therapy for some localized and almost all metastatic prostate cancer (PCa) patients. Although several clinical cohort studies have identified an impact of ADT on the cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer’s […]
• The Microbiome of Catheter-Collected Urine in Males with Bladder Cancer according to Disease Stage.29th August 2020
  The dogma that urine is sterile has been overturned and dysbiosis of the urinary microbiome has been linked to many urological disorders. We tested the hypothesis that the urinary microbial composition may be different between men with or without bladder cancer in catheter-collected urines, bladder washouts and midstream voided urines, and may be dependent on […]
• The Risk of New Onset Dementia And/Or Alzheimer’s Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis.29th August 2020
  Androgen deprivation therapy (ADT) is a standard therapy for some localized and almost all metastatic prostate cancer (PCa) patients. Although several clinical cohort studies have identified an impact of ADT on the cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer’s […]
• Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.28th August 2020
  Infigratinib (BGJ398) is a potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor with significant activity in metastatic urothelial carcinoma (mUC) bearing FGFR3 alterations. It can cause hyperphosphatemia due to the “on-target” class effect of FGFR1 inhibition.To investigate the relationship between hyperphosphatemia and treatment response in patients with mUC.Oral infigratinib 125 mg/d for 21 d every […]
• Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.21st August 2020
  Standard of care for patients with muscle-invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC) followed by consolidative therapy with either chemoradiation or radical cystectomy (RC). Some patients experience robust pathologic responses to NAC, and these have been reported to associate with somatic mutations in specific gene pathways including DNA damage response genes.To evaluate the […]
• Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.20th August 2020
  The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel previously. In a prior analysis, the trial’s primary endpoint (overall survival [OS]) was not improved significantly.To report the final analysis of OS.A total of 799 patients were randomized […]